Anti-IZUM3/ IZUMO3/ C9orf134 monoclonal antibody

Anti-IZUM3/ IZUMO3/ C9orf134 antibody for FACS & in-vivo assay

Target products collectionGo to IZUMO3/IZUMO3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0647-Ab-1/ GM-Tg-hg-MP0647-Ab-2Anti-Human IZUMO3 monoclonal antibodyHuman
GM-Tg-rg-MP0647-Ab-1/ GM-Tg-rg-MP0647-Ab-2Anti-Rat IZUMO3 monoclonal antibodyRat
GM-Tg-mg-MP0647-Ab-1/ GM-Tg-mg-MP0647-Ab-2Anti-Mouse IZUMO3 monoclonal antibodyMouse
GM-Tg-cynog-MP0647-Ab-1/ GM-Tg-cynog-MP0647-Ab-2Anti-Cynomolgus/ Rhesus macaque IZUMO3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0647-Ab-1/ GM-Tg-felg-MP0647-Ab-2Anti-Feline IZUMO3 monoclonal antibodyFeline
GM-Tg-cang-MP0647-Ab-1/ GM-Tg-cang-MP0647-Ab-2Anti-Canine IZUMO3 monoclonal antibodyCanine
GM-Tg-bovg-MP0647-Ab-1/ GM-Tg-bovg-MP0647-Ab-2Anti-Bovine IZUMO3 monoclonal antibodyBovine
GM-Tg-equg-MP0647-Ab-1/ GM-Tg-equg-MP0647-Ab-2Anti-Equine IZUMO3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0647-Ab-1/ GM-Tg-hg-MP0647-Ab-2; GM-Tg-rg-MP0647-Ab-1/ GM-Tg-rg-MP0647-Ab-2;
GM-Tg-mg-MP0647-Ab-1/ GM-Tg-mg-MP0647-Ab-2; GM-Tg-cynog-MP0647-Ab-1/ GM-Tg-cynog-MP0647-Ab-2;
GM-Tg-felg-MP0647-Ab-1/ GM-Tg-felg-MP0647-Ab-2; GM-Tg-cang-MP0647-Ab-1/ GM-Tg-cang-MP0647-Ab-2;
GM-Tg-bovg-MP0647-Ab-1/ GM-Tg-bovg-MP0647-Ab-2; GM-Tg-equg-MP0647-Ab-1/ GM-Tg-equg-MP0647-Ab-2
Products NameAnti-IZUMO3 monoclonal antibody
Formatmab
Target NameIZUMO3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-IZUMO3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species IZUM3/ IZUMO3/ C9orf134 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0647
    Target NameIZUMO3
    Gene ID100129669,69314,100362588,106993723,102153917,102901386,786878,100630134
    Gene Symbol and Synonyms1700011H22Rik,bA20A20.1,C9orf134,IZUMO3
    Uniprot AccessionQ5VZ72,A6QL94
    Uniprot Entry NameIZUM3_HUMAN,IZUM3_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000205442
    Target ClassificationN/A

    The target: IZUMO3, gene name: IZUMO3, also named as C9orf134, bA20A20.1. Predicted to enable protein homodimerization activity. Predicted to be located in plasma membrane. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.